Latest News

F5 (FFIV) is under close watch after disclosing a sophisticated nation state cyberattack that hit its BIG-IP product development environment, prompted revenue forecast revisions, and triggered multiple securities class action lawsuits questioning earlier disclosures. See our latest analysis for F5. F5's US$269.31 share price has seen a 4.94% 7 day share price return and a 4.35% 30 day share price return, while the 1 year total shareholder return of 5.89% contrasts with a much stronger 3 year...

SmartStop Self Storage REIT (SMA) has been drawing attention after recent trading, with the stock last closing at $32.22. Short term returns are mixed, which has some investors revisiting fundamentals and valuation. See our latest analysis for SmartStop Self Storage REIT. That recent 1-day share price return of 1.77% and 7-day share price return of 4.75% sit against a year to date share price return of 4.75%, while the 90-day share price return of 7.71% indicates that momentum has been fading...

In early January 2026, Harmony Biosciences Holdings drew renewed attention as it advanced clinical programs for WAKIX and other rare neurological disease candidates while preparing for a company presentation at the J.P. Morgan Healthcare Conference. This combination of an expanding pipeline, solid reported profitability, and predominantly positive analyst sentiment has sharpened investor focus on the company’s long-term prospects. Now we’ll examine how Harmony’s progress with WAKIX and its...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Adcorp...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Atlas Copco's (STO:ATCO A) stock is up by 8.3% over the past three months. Given that the market rewards strong...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

While Eckert & Ziegler SE ( ETR:EUZ ) might not have the largest market cap around , it saw a decent share price growth...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Despite an already strong run, Viridien Société anonyme ( EPA:VIRI ) shares have been powering on, with a gain of 26...

Key Insights Institutions' substantial holdings in Nobia implies that they have significant influence over the...

To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...

If you are wondering whether Chubb's current share price lines up with its underlying value, you are not alone, and that is exactly what this article will help you unpack. Chubb shares last closed at US$306.81, with returns of a 1% decline over the past week, 3.5% over the past month, a 1% decline year to date, 20.6% over the past year, 41% over three years, and 113.6% over five years, which can influence how investors think about both growth potential and risk today. Recent headlines around...

In early January 2026, RBC reiterated its positive view on Trisura Group after December 2025 excess and surplus insurance stamping office data from California, Florida, and Texas showed a strong pickup in sector premiums. This sector-level acceleration in key U.S. specialty markets is being interpreted as a supportive signal for Trisura’s opportunity set in excess and surplus lines. We’ll now examine how the strengthening excess and surplus premium trends could influence Trisura Group’s...

Mirum Pharmaceuticals (MIRM) has drawn attention after initiating the BLOOM Phase 2 trial of MRM-3379 in Fragile X syndrome, alongside fresh institutional interest and recent revenue growth that some investors interpret as a sign of business momentum. See our latest analysis for Mirum Pharmaceuticals. The recent 6.09% 1 day share price return and 33.86% 30 day share price return, taking Mirum to $86.57, line up with the Phase 2 trial news, institutional buying and revenue growth. At the same...

L'Air Liquide (ENXTPA:AI) is back in the spotlight as investors focus on its ADVANCE 2025 plan, particularly large projects tied to energy transition, low carbon hydrogen, and decarbonization across industrial, healthcare, and electronics markets. See our latest analysis for L'Air Liquide. L'Air Liquide's share price has recently been more muted, with a 6.37% decline over the past 90 days. However, the 1 year total shareholder return of 3.57% and 5 year total shareholder return of 58.95%...

In early January 2026, Raymond James downgraded MPLX from Outperform to Market Perform, following JP Morgan’s earlier move to lower its rating as analysts flagged limited organic growth prospects and a heavier reliance on mergers and acquisitions. At the same time, MPLX reported higher quarterly revenue and net profit than a year earlier and scheduled a February 3, 2026 earnings call, setting up a contrast between improving recent results and more cautious views on its longer-term growth...

Amcor (AMCR) is back in focus after a series of upbeat analyst views, reaffirmed fiscal 2026 guidance and fresh insider share purchases tied to its Berry Global acquisition and planned synergy gains. See our latest analysis for Amcor. Against this backdrop, Amcor’s share price has moved to US$8.65, with a 90 day share price return of 9.08% and a 30 day gain of 5.49%. This suggests momentum has been building, even as the 1 year total shareholder return of 2.68% decline and 3 year total...

Truist Securities’ recent coverage initiation on Lemonade (LMND) with a Buy rating has put the insurer back on many watchlists and has prompted fresh questions about how today’s price reflects its current fundamentals. See our latest analysis for Lemonade. The Truist initiation comes after a strong run, with Lemonade’s 90 day share price return of 65.8% and a one year total shareholder return of 146.52% suggesting momentum has recently been building from a low base despite some earlier long...

Grid Dynamics Holdings (GDYN) is back on investors’ radar after entering a multi-year collaboration with Amazon Web Services centered on generative AI solutions for enterprise clients, framed against fresh insider stock sales and equity plan changes. See our latest analysis for Grid Dynamics Holdings. The AWS collaboration arrives after a choppy period for shareholders, with a 25% 90 day share price return contrasted by a 53.17% decline in 1 year total shareholder return. Recent momentum is...

In early 2026, Expedia Group’s operational progress came into focus as analysts highlighted stronger room night growth, improved marketing efficiency, and EBITDA margin expansion under CEO Ariane Gorin’s updated re‑platforming and loyalty strategy. At the same time, OpenAI’s integration of trip‑booking with Expedia into the ChatGPT experience underscored how consumer AI and real‑world travel marketplaces may increasingly intersect rather than be easily disrupted. We’ll now examine how this...

In recent days, Cleveland-Cliffs faced an analyst downgrade from KeyBanc to sector weight, citing softer auto-related demand and slightly higher costs, even as its cooperation with POSCO was highlighted as a positive for its operations and finances. Despite this more cautious analyst stance, trading activity appears heavily influenced by technical signals and elevated short interest, suggesting market positioning is playing an important role in how investors are reacting to the company. With...

Alexandria Real Estate Equities recently reported weaker third-quarter 2025 results, recorded a US$323.90 million real estate impairment including US$206.00 million on its Long Island City asset, cut its dividend by 45%, and now faces multiple securities class action lawsuits over alleged misstatements about that property and its leasing prospects. The combination of muted tenant demand, pressure on life science leasing, rising short interest, and legal scrutiny around the Long Island City...